• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
LI Ling,HUANG Xin,LI Yan,HU Mengdi,XU Lu.Metformin reversed acquired resistance to tamoxifen in breast cancer via NF-κB signaling pathway[J].Journal Of Pharmaceutical Research,2024,43(10):943-947[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2740times   Download 2884次 QR Code for this article
Scan with your phone!
二甲双胍通过抑制NF-κB信号通路克服乳腺癌他莫昔芬获得性耐药
李羚1,黄欣1,李妍1,胡梦笛2,徐璐2
Font:Larger+|Default|Smaller-
(1.山东第一医科大学第一附属医院<山东省千佛山医院>临床药学,山东省儿童药物临床评价与研发工程技术研究中心,山东 济南 250014;2.上海交通大学医学院药理学与化学生物学系,上海 200021)
摘要:
目的 探讨二甲双胍克服乳腺癌他莫昔芬获得性耐药的作用及其机制。方法 采用CCK-8和集落形成实验检测细胞增殖;采用流式细胞术检测细胞凋亡;采用Western blotting检测Cleaved-PARP和NF-κB p65的蛋白表达。免疫荧光分析用于检测NF-κB p65的核转位。结果 发现二甲双胍能抑制乳腺癌细胞和他莫昔芬获得性耐药细胞的增殖并促进其凋亡。二甲双胍能够延缓乳腺癌细胞对他莫昔芬产生获得性耐药。此外,二甲双胍抑制了NF-κB信号通路。结论 二甲双胍通过抑制NF-κB信号通路克服乳腺癌他莫昔芬获得性耐药,该研究为寻找克服他莫昔芬获得性耐药的治疗提供了潜在候选药物。
关键词:  二甲双胍  乳腺癌  获得性耐药  他莫昔芬  核转录因子κB
DOI:10.13506/j.cnki.jpr.2024.10.002
基金项目:国家自然科学基金项目(No.82104222);山东省自然科学基金项目(No.ZR2021QH247);山东省千佛山医院培育基金项目(No.QYPY2021NSFC0612);白求恩公益基金会(No.Z04JKM2023E040);山东省医学会齐鲁专项(No.YXH2022ZX02048)
Publication Date:October 30, 2024
Metformin reversed acquired resistance to tamoxifen in breast cancer via NF-κB signaling pathway
LI Ling1,HUANG Xin1,LI Yan1,HU Mengdi2,XU Lu2
(1.Shandong Engineering and Technology Research Center for Pediatric Drug Development,Shandong Medicine and Health Key Laboratory of Clinical Pharmacy,Department of Clinical Pharmacy,The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital,Jinan 250014, China;2.Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200021, China)
Abstract:
Objective To explore the function and mechanism of Metformin in overcoming acquired resistance to tamoxifen in breast cancer. Methods CCK-8 and colony formation assays were conducted to detect cell proliferation. Flow cytometry was employed to detect cell apoptosis. Western blotting was applied to detect the protein expression of cleaved-PARP and NF-κB p65. Immunofluorescence analysis was used to detected the NF-κB p65 nuclear translocation. Results We found that Metformin inhibited proliferation and promoted apoptosis of breast cancer cells and acquired resistant cells. Metformin significantly delayed the emergence of acquired resistance to tamoxifen. In addition, Metformin could inhibit NF-κB signaling pathway. Conclusion Metformin reversed acquired resistance to tamoxifen in breast cancer via NF-κB signaling pathway. Our study repurposes Metformin as a potential candidate for overcoming acquired resistance to tamoxifen.
Key words:  Metformin  Breast cancer  Acquired resistance  Tamoxifen
Today's Visits:487    Total Visits:2383201
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.